ArticlePostepy dermatologii i alergologii2024
Regulation of involucrin and signalling pathway in scleroderma epidermal keratinocytes.
Article in Postepy dermatologii i alergologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Systemic sclerosis is a complex disease characterized by the fibrosis and vasculopathy. Aim: We aimed to assess scleroderma by examining involucrin, an early terminal differentiation marker of epidermal keratinocytes. Material and methods: Immunolocalization of involucrin was performed in healthy controls and patients with scleroderma lesions by using an immunofluorescence (IF) assay. Normal and scleroderma keratinocytes were incubated in low-Ca basal-defined K-SFM overnight. Cells were pre-treated with Y-27632 (a Rho signalling pathway inhibitor) or interleukins (ILs), tumor necrosis factor-α (TNF-α), transforming growth factor β1 (TGF-β1), endothelin-1 (ET-1), interferon-γ (IFN)-γ, vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) - BB. The involucrin protein expression level was measured by western blot. Results: Compared with the normal skin, involucrin was detected in the granular layer and the upper stratum spinosum in patients with scleroderma lesions. However, involucrin protein expression was decreased in cultured scleroderma keratinocytes. IL-6, IL-10, IL-17A, TNF-α, TGF-β1, ET-1, IFN-γ, VEGF165, and PDGF-BB increased involucrin expression in normal keratinocytes but decreased it in scleroderma keratinocytes. IFN-γ and IL-13 remarkably downregulated involucrin levels in normal and scleroderma keratinocytes, respectively, by Y-27632 intervention. Conclusions: Inflammatory cytokines, such as IL-6, IL-10, TGF-β1, ET-1, IFN-γ, VEGF, PDGF-BB, and Rho signalling pathway may be associated with the delayed epidermal differentiation in scleroderma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.